← Leaderboards
Philippe O Szapary
University Of Pennsylvania
$2,140,747
Attributed
$2,140,747
Total exposure
10
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,140,747 · 10
By mechanism
R21$792,500 · 3
K23$762,271 · 1
M01$585,976 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Thomas A. Wadden$34,016,838
- Stephen G Emerson$28,932,839
- Garret A Fitzgerald$242,218,424
- Melpo Christofidou-Solomidou$5,805,617
- Francesca Catella-Lawson$1,843,768
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationDietary SupplementsAlternative MedicineAtherosclerosisPlant ExtractsClinical TrialsOxidative StressDrug Screening /EvaluationLipid MetabolismAntiinflammatory AgentsCardiovascular Disorder PreventionPatient Oriented ResearchCardiovascular Disorder ChemotherapyCombination ChemotherapyDrug Adverse EffectDisease /Disorder Prevention /ControlCardiovascular Disorder TherapyNutrition Related TagHypercholesterolemiaDiet TherapyCardiovascular Disorder RiskCholesterol
Grant awards (18)
CHROMIUM PICOLINATE IN METABOLIC SYNDROME$103,283
M01 · FY2005 · RR
DEVELOPMENT OF THE PHILADELPHIA AREA METABOLIC SYNDROME NETWORK (PAMSYN)$88,284
M01 · FY2005 · RR
CURCUMINOID STUDY$74,650
M01 · FY2005 · RR
THE EFFECT OF PIOGLITAZONE ON THE HDL-TRIGLYCERIDE AXIS IN NON-DIABETIC PATIENTS$46,358
M01 · FY2005 · RR
FLAXSEED IN REDUCING CARDIOVASCULAR RISK IN PATIENTS W/ PRIMARY HYPERCHOLESTERAL$682
M01 · FY2005 · RR
Cardiovascular Effects of lyengar Yoga$198,125
R21 · FY2004 · AT
The Safety and Efficacy of Flaxseed in Reducing Cardiovascular Risk$182,168
M01 · FY2004 · RR
AYURVEDIC HERBALS: EFFECTS ON LIPIDS &ATHEROSCLEROSIS$150,423
K23 · FY2004 · AT
Non-Diabetic Patients with Metabolic Syndrome$62,143
M01 · FY2004 · RR
Change of Heart Pilot Project$17,400
M01 · FY2004 · RR
Anti-Inflammatory, Antiplatelet and Antioxidant Effects of Curcuminoids$11,008
M01 · FY2004 · RR
Chromium Picolinate in the Metabolic Syndrome$198,125
R21 · FY2003 · DK
Flax: Safety &Efficacy in Reducing Cardiovascular Risk$198,125
R21 · FY2003 · AT
AYURVEDIC HERBALS: EFFECTS ON LIPIDS &ATHEROSCLEROSIS$151,137
K23 · FY2003 · AT
Flax: Safety &Efficacy in Reducing Cardiovascular Risk$198,125
R21 · FY2002 · AT
AYURVEDIC HERBALS: EFFECTS ON LIPIDS &ATHEROSCLEROSIS$152,262
K23 · FY2002 · AT
AYURVEDIC HERBALS: EFFECTS ON LIPIDS &ATHEROSCLEROSIS$153,289
K23 · FY2001 · AT
AYURVEDIC HERBALS: EFFECTS ON LIPIDS &ATHEROSCLEROSIS$155,160
K23 · FY2000 · AT